Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997.
D001943:Breast Neoplasms / Q000150:complications* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000172:deficiency* / Q000378:metabolism; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007529:Isoflavones; D008593:Menopause; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D048789:Phytoestrogens; D010880:Piperidines / Q000494:pharmacology; D028321:Plant Preparations; D020849:Raloxifene Hydrochloride; D011960:Receptors, Estrogen / Q000378:metabolism; D017741:Survivors
D004965:Estrogen Antagonists; D004967:Estrogens; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D048789:Phytoestrogens; D010880:Piperidines; D028321:Plant Preparations; D011960:Receptors, Estrogen; D020849:Raloxifene Hydrochloride